GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence

Clinical Trial ID NCT00376272

Rank	Title	Journal	Year	PubWeight™‹?›
1	Valsartan for prevention of recurrent atrial fibrillation.	N Engl J Med	2009	3.60
2	Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.	Circulation	2009	3.50
3	The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.	Heart Rhythm	2008	1.03
4	Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.	Am Heart J	2010	0.91
5	Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.	Am Heart J	2011	0.89
6	Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial.	BMC Cardiovasc Disord	2013	0.86
7	Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.	J Cardiovasc Med (Hagerstown)	2006	0.85
8	Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy.	Circ Cardiovasc Imaging	2011	0.79